CSL Ltd. — Investor Presentation 2023

May 28, 2023

For immediate release

29 May 2023

==> picture [596 x 198] intentionally omitted <==

CSL Shareholder Briefings

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

CSL will be meeting with its shareholders today in Brisbane (Monday, 29 May 2023) and tomorrow in Sydney (Tuesday, 30 May 2023). The presentation materials for these meetings are attached for the information of investors.

A recording of the presentation will be available in the ‘investors’ section of the Company website at www.csl.com under Presentations.

Authorised for release by:

==> picture [86 x 40] intentionally omitted <==

Fiona Mead Company Secretary

Investors: Bernard Ronchi Investor Relations CSL Limited P: +61 3 9389 3470 E: bernard.ronchi@csl.com.au

Media: Jimmy Baker Communications CSL Limited P: +61 450 909 211

E: jimmy.baker@csl.com.au

Shareholder Briefing May 2023

Joy Linton Chief Financial Officer

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

2

Joy Linton CFO

==> picture [109 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

3

CSL – Leading Global Biotech

5[th] Largest Global Biotech

Global #1 in protein therapies ~$37 billion industry

32,000+

Global #2 in influenza vaccines $6 billion industry

Global #1 in iron

• ~ $5 billion industry

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

4

Our Businesses

==> picture [106 x 55] intentionally omitted <==

==> picture [166 x 35] intentionally omitted <==

Biotherapies & Rare Disease

==> picture [161 x 35] intentionally omitted <==

Vaccines

==> picture [125 x 29] intentionally omitted <==

Iron Deficiency & Nephrology

Driven by Our Promise

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

5

Global Manufacturing Presence

==> picture [138 x 30] intentionally omitted <==

==> picture [160 x 79] intentionally omitted <==

==> picture [160 x 79] intentionally omitted <==

==> picture [161 x 79] intentionally omitted <==

==> picture [160 x 79] intentionally omitted <==

==> picture [160 x 79] intentionally omitted <==

Bern, Broadmeadows, Marburg, Switzerland Australia Germany

Kankakee, IL, U.S.

Wuhan, China

• • •

• Core products: Toll plasma Core products: immunoglobulins, fractionation services coagulation factors, albumin for Australia, critical care

  • •

  • Core products: albumin, Core products: albumin, intermediate pastes immunoglobulins

• albumin for Australia, critical care • Specialty products:

• • • Specialty products: New Zealand, Hong Specialty products: coagulation factors, albumin, anti-DKong, Malaysia, hyperimmunes alpha1-proteinase hyperimmune Singapore and Taiwan inhibitor

• Core products: coagulation factors, critical care, immunoglobulins

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

6

Global Manufacturing Presence

==> picture [134 x 29] intentionally omitted <==

==> picture [202 x 101] intentionally omitted <==

Parkville, Australia

Only influenza vaccine manufacturing facility in Australia and the world’s only manufacturer of Q fever vaccine and local antivenoms

==> picture [104 x 10] intentionally omitted <==

==> picture [202 x 101] intentionally omitted <==

Holly Springs, NC, U.S.

Largest cell-based influenza vaccine manufacturing facility in the world

==> picture [202 x 101] intentionally omitted <==

Liverpool,

U.K.

Only injectable influenza vaccine facility in the U.K. One of the largest biotech sites in Europe

==> picture [106 x 24] intentionally omitted <==

==> picture [204 x 100] intentionally omitted <==

St Gallen, Switzerland

Active pharmaceutical ingredient production of iron therapies

==> picture [67 x 50] intentionally omitted <==

7

Strong and Consistent Growth US$

==> picture [846 x 319] intentionally omitted <==

----- Start of picture text -----

Revenue Net Profit Dividends
$10.6b $2.3b $2.22
8% 9% 10%
CAGR CAGR CAGR
$1.0b
$4.8b
$0.865
2012 2022 2012 2022
2012 2022
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

8

1H23 Performance

Ig franchise growing strongly CSL Vifor progressing well

==> picture [271 x 150] intentionally omitted <==

CSL Behring

• Ig franchise growing strongly

• Record levels of plasma collections

CSL Vifor

• Successful acquisition closure

• ~5 months financial contribution

CSL Seqirus

• Strong sales growth driven by differentiated products

• Licence agreement for latestage self amplifying mRNA vaccine technology

R&D

• Gene therapy HEMGENIX[®] approved

• Multiple late stage programs

$7.18b +25%[1] REVENUE

$1.62b[2] 0%[1] NPAT

Incl. one-off costs associated with Vifor acquisition

==> picture [88 x 51] intentionally omitted <==

----- Start of picture text -----

$1.82b [2]
+10% [1]
NPATA [3]
----- End of picture text -----

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.. 2. Attributable to the shareholders of CSL Limited

3. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and acquisition accounting related adjustments.

9

Long Term, Sustainable Growth

1 Consistent strategy & disciplined execution 2 Targeted R&D with persistent innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

10

Long Term, Sustainable Growth

1 Consistent strategy & disciplined execution 2 Targeted R&D with persistent innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

11

Our 2030 Strategy

Focusing Innovating Delivering Growing Transforming in therapeutic across our reliable supplies of our our pipeline with our digital intellect areas where organization products as efficiently sustainable, trusted and technologies we excel as possible R&D platforms

==> picture [104 x 10] intentionally omitted <==

==> picture [568 x 295] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

12

Investing to serve unmet patient needs

US$m US$b Capex Revenue 1,400 12 1,200 10 1,000 8 800 6 600 4 400 2 200 - -

==> picture [257 x 458] intentionally omitted <==

----- Start of picture text -----

•
60-70% in growth capex
v maintenance capex
over the last 5 years
•
FY23 expected to be
~$1.2b
----- End of picture text -----

Maint Growth Revenue

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

13

Long Term, Sustainable Growth

1 Consistent strategy & disciplined execution 2 Targeted R&D with persistent innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

14

Focus Through Our Therapeutic Areas

==> picture [960 x 147] intentionally omitted <==

CSL Vifor adds iron and nephrology

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

15

Expanding R&D’s Global Footprint

==> picture [560 x 173] intentionally omitted <==

----- Start of picture text -----

Tullamarine, AU Marburg, DE
----- End of picture text -----

==> picture [560 x 176] intentionally omitted <==

----- Start of picture text -----

Waltham, MA, US
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

==> picture [275 x 355] intentionally omitted <==

----- Start of picture text -----

Melbourne, AU
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

16

R&D Portfolio – FY22

==> picture [813 x 412] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

17

Significant Target Launch Dates[1]

==> picture [836 x 359] intentionally omitted <==

----- Start of picture text -----

FY23 FY24 - FY27
HEMGENIX [®] Garadacimab CSL112 FERINJECT [® ]
Etranacogene Anti-FXIIa (HAE) ApoA-1 (AMI) Ferric carboxymaltose
dezaparvovec (Haem B) (ID) China
BERINERT [® ] SC HIZENTRA [®] Adjuvanted Cell Culture Sparsentan
C1 Esterase Inhibitor (HAE) SCIg 20% Liquid (DM) Influenza Vaccine Dual ETA & AT1 antagonist
Japan (aQIVc) (IgAN) EU
INJECTAFER [® ] Clazakizumab ARCT-154 COVID Vaccine Sparsentan
Ferric carboxymaltose Anti-IL-6 (AMR) Dual ETA & AT1 antagonist
(ID-HF) US (FSGS) EU
CSL964 AAT SNF472
(GvHD Treatment) Calcification inhibitor
(CUA)
Immunology Haematology Cardiovascular & Metabolic Transplant
Vaccines CSL Vifor Partnered Projects
----- End of picture text -----

1. Launch subject to clinical completion, submission and regulatory approval

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

18

Long Term, Sustainable Growth

1 Consistent strategy & disciplined execution 2 Targeted R&D with persistent innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

19

==> picture [257 x 200] intentionally omitted <==

CSL is committed to a healthier world. Our vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a values-driven culture

==> picture [104 x 10] intentionally omitted <==

Creating Value

==> picture [57 x 56] intentionally omitted <==

A healthy, more productive society Sustainable Our financial growth Promise to patients Social and economic opportunity

==> picture [79 x 79] intentionally omitted <==

==> picture [88 x 88] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

20

Sustainability – 3 Key Strategic Pillars

ENVIRONMENT (E)

SOCIAL (S)

SUSTAINABLE WORKFORCE (W)

• E1 Integrate sustainability S1 Being trusted by donors through a focus on their

• considerations into business experience and wellbeing,

• decisions and their communities

• S2 Strengthen societal health

• E2 Reduce carbon emissions through access to our existing products and therapies

• E3 and investment in innovation Minimise end to end production of waste through removal, reduction & S3 * Enhance our industry position recycling as a patient-focussed leader

• E4 Reduction of carbon by communicating our emissions/waste in our impact on patients and supply chain community health

• W1 Raise awareness, visibility and engagement of sustainability across the end-to-end working experience for our employees.

W2 Communicate to, and engage with employees in programs that maximise diversity, equity and inclusion

W3 Ensure all CSL employees have access and opportunity to participate in community giving programs and volunteerism for local needs

Across All Pillars We Shall Innovate, Partner, Engage Employees, Actively Communicate

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

21

Sustainability – Environment Carbon emissions reduction targets

Scope 1 & 2

Scope 3

A reduction of 40% of absolute Scope 1 & 2 emissions against a baseline of the average annual emissions across FY19-21 by 2030

Ensure suppliers who contribute 67% of Scope 3 emissions set Scope 1 & 2 reduction targets by 2030 aligned with Science Based Targets initiative

Scope 3

Scope 1 & 2

Abatement Levers

Abatement Levers

• Revised procurement standards and award criteria

• Increased energy efficiency

• A push towards more renewable power

• Supplier enablement through advocacy and education

• Switching fuels to less carbon intensive energy sources

• Strategic partnerships to innovate and collaborate

• Re-designing some of our manufacturing sites

==> picture [104 x 10] intentionally omitted <==

==> picture [318 x 156] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

22

Positive Market Fundamentals

CSL Behring

• Strong plasma collections and Ig growth expected to continue

• Gene therapy HEMGENIX[®] US commercialisation

CSL Seqirus

• Demand for differentiated high value products to remain robust

CSL Vifor

• Untapped potential in iron

• Renal market expected to grow at low double digits in mid term

R&D portfolio progressing

==> picture [104 x 10] intentionally omitted <==

==> picture [243 x 419] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

23

Long Term, Sustainable Growth

1 Consistent strategy & disciplined execution 2 Targeted R&D with persistent innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

24

==> picture [122 x 108] intentionally omitted <==

Thank You / Questions

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

25